美国血液技术(HAE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HAE 美国血液技术

交易中 11-21 14:25:49 EST

85.33

+0.41

+0.48%

最高86.66	最低84.42	成交量34.04万
今开84.90	昨收84.92	日振幅2.64%
总市值42.85亿	流通市值42.42亿	总股本5,022万
成交额2,917万	换手率0.68%	流通股本4,972万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"HAE","market":"US","secType":"STK","nameCN":"美国血液技术","latestPrice":85.325,"timestamp":1732217146299,"preClose":84.92,"halted":0,"volume":340402,"delay":0,"floatShares":49719543,"shares":50223887,"eps":2.410061,"marketStatus":"交易中","marketStatusCode":2,"change":0.405,"latestTime":"11-21 14:25:49 EST","open":84.9,"high":86.66,"low":84.42,"amount":29172924.55878,"amplitude":0.026378,"askPrice":85.39,"askSize":104,"bidPrice":85.31,"bidSize":15,"shortable":3,"etf":0,"ttmEps":2.410061,"exchange":"NYSE","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1732222800000},"adr":0,"listingDate":673761600000,"adjPreClose":84.92,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":85,"preClose":84.92,"latestTime":"09:16 EST","volume":88,"amount":7457.6304,"timestamp":1732198581028},"postHourTrading":{"tag":"盘后","latestPrice":84.92,"preClose":84.92,"latestTime":"16:02 EST","volume":12476,"amount":1059461.92,"timestamp":1732136536298},"volumeRatio":0.706312,"impliedVol":0.3649,"impliedVolPercentile":0.3254},"requestUrl":"/m/hq/s/HAE","defaultTab":"news","newsList":[{"id":"2484510190","title":"美国血液技术2024财年第三财季实现净利润33.83百万美元，同比增加35.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484510190","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484510190?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:00","pubTimestamp":1731772808,"startTime":"0","endTime":"0","summary":"11月17日，美国血液技术公布财报，公告显示公司2024财年第三财季净利润为33.83百万美元，同比增加35.81%；其中营业收入为3.46亿美元，同比增加8.81%，每股基本收益为0.66美元。从资产负债表来看，美国血液技术总负债16.46亿美元，其中短期债务5.43百万美元，资产负债比为1.54，流动比率为3.49。机构评级：截至2024年11月17日，当前有10家机构对美国血液技术目标价做出预测，其中目标均价为110.80美元，其中最低目标价为85.00美元，最高目标价为125.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000019abc78df6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000019abc78df6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HAE"],"gpt_icon":0},{"id":"1124602679","title":"异动解读 | 美国血液技术财报超预期  股价大涨近8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124602679","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124602679?lang=zh_cn&edition=full","pubTime":"2024-11-08 11:08","pubTimestamp":1731035333,"startTime":"0","endTime":"0","summary":"周二,医疗器械制造商美国血液技术公司(HAE)公布了2024财年第三季度财报,超出市场预期,公司股价当日大涨7.47%,引发市场关注。\n\n财报显示,美国血液技术第三季度调整后每股收益为1.12美元,高于分析师平均预期的1.07美元。该公司本季度营收同比增长8.6%,达到3.4551亿美元,虽略低于预期的3.4265亿美元,但整体表现依然出色。\n\n分析师对美国血液技术的长期前景持乐观态度。目前分析师平均给予该公司\"买入\"评级,预计其未来12个月股价目标中位数为113.5美元。分析人士认为,作为医疗设备和用品行业的龙头企业,该公司在技术、研发和渠道优势等多方面具备良好发展潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HAE"],"gpt_icon":0},{"id":"1141327239","title":"异动解读 | 美国血液技术(HAE)公布强劲财报 股价大涨7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1141327239","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141327239?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:37","pubTimestamp":1730990222,"startTime":"0","endTime":"0","summary":"美国血液技术公司公布了截至2024年9月30日的2024财年第三季度财报,业绩超出分析师预期,股价当日大涨7.47%,引发市场热议。财报显示,美国血液技术当季度调整后每股收益为1.12美元,超过分析师平均预期的1.07美元。分析师对美国血液技术的长期前景持乐观态度。目前分析师平均对该公司股票的评级为\"买入\",预计其未来12个月股价目标中位数为113.5美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HAE"],"gpt_icon":0},{"id":"2481189956","title":"美国血液技术盘中异动 早盘股价大涨8.75%报85.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481189956","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481189956?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:34","pubTimestamp":1730990066,"startTime":"0","endTime":"0","summary":"北京时间2024年11月07日22时34分，美国血液技术股票出现异动，股价快速拉升8.75%。截至发稿，该股报85.00美元/股，成交量7987股，换手率0.02%，振幅1.36%。美国血液技术股票所在的医疗设备行业中，整体涨幅为0.14%。美国血液技术公司简介：美国血液技术公司旨在通过在血液和血浆成分采集、外科病房和医院输血服务空间提供医疗产品和解决方案，改善患者护理，降低医疗保健成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110722342695bde6e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110722342695bde6e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0205194284.USD","LU0012050646.USD","BK4198","IE00BLDYK493.USD","IE00B64QTZ34.USD","LU1169589451.USD","LU0205193047.USD","LU1169590202.USD","LU0106261612.USD","HAE"],"gpt_icon":0},{"id":"1117245921","title":"异动解读 | 美国血液技术财报超预期 盘前股价大涨6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117245921","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117245921?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:31","pubTimestamp":1730989880,"startTime":"0","endTime":"0","summary":"美国血液技术(HAE)公司周二盘前股价大涨6.19%,投资者对其最新财报业绩表现反应热烈。\n\n美国血液技术公司公布的截至9月30日的季度调整后每股收益为1.12美元,超出分析师预期的1.07美元。该公司本季度营收同比增长8.6%至3.4551亿美元,但略低于分析师3.4265亿美元的预期区间。\n\n尽管营收略有失算,但美国血液技术依然交出了可观的业绩。分析师普遍看好该公司长期前景,给予\"买入\"的评级。分析师认为,公司在医疗设备、用品和分销领域具有良好的发展潜力,预计其未来12个月股价目标中位数为113.5美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HAE"],"gpt_icon":0},{"id":"2481756183","title":"Haemonetics 公司公布截至 9 月 30 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2481756183","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481756183?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:21","pubTimestamp":1730989261,"startTime":"0","endTime":"0","summary":"   * Haemonetics Corp   公布的截至9月30日的季度调整后每股收益为1.12美元，高于去年同期的每股收益99美分。10位分析师对该季度的平均预期为每股收益1.07美元。华尔街预期为每股收益 1.03 美元至 1.10 美元。* Haemonetics 公司公布的本季度每股收益为 66 美分。* 公司报告的季度净收入为3383万美元。* Haemonetics Corp本季度股价下跌了2.8%，今年迄今为止下跌了8.6%。华尔街对 Haemonetics 公司 12 个月目标价的中位数为 113.50 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Haemonetics 公司公布截至 9 月 30 日的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106261612.USD","LU0205193047.USD","IE00BLDYK493.USD","LU1169590202.USD","IE00B64QTZ34.USD","LU0205194284.USD","LU1169589451.USD","BK4198","HAE","LU0012050646.USD"],"gpt_icon":0},{"id":"2477630596","title":"BUZZ-基因治疗研究中期数据不尽如人意，Intellia业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2477630596","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477630596?lang=zh_cn&edition=full","pubTime":"2024-10-24 22:31","pubTimestamp":1729780273,"startTime":"0","endTime":"0","summary":"** HAE的特征是皮肤、胃肠道、上呼吸道系统、面部和喉咙不可预测地频繁出现严重肿胀。** 我们预计，考虑到体内基因编辑的潜在风险和该适应症的竞争格局，投资者会认为 HAE 发作减少 75-80% 的结果并不令人印象深刻。** 美国目前批准的HAE治疗药物包括武田药品  和BioCryst Pharmaceuticals  生产的药物。** 包括盘中走势在内，Intellia 的股价今年以来下跌了约 46","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLDYK493.USD","LU0205193047.USD","HAE","BK4198","LU1169590202.USD","LU0012050646.USD","NTLA","BK4139","LU0205194284.USD","BK4535","LU0106261612.USD","LU1861559042.SGD","IE00B64QTZ34.USD","BK4556","BK4588","LU1169589451.USD","BK4547","BCRX","LU1861558580.USD","BK4585"],"gpt_icon":0},{"id":"2470508715","title":"美国血液技术盘中异动 快速拉升5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2470508715","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470508715?lang=zh_cn&edition=full","pubTime":"2024-09-27 22:49","pubTimestamp":1727448561,"startTime":"0","endTime":"0","summary":"北京时间2024年09月27日22时49分，美国血液技术股票出现异动，股价急速拉升5.17%。截至发稿，该股报80.51美元/股，成交量27.8626万股，换手率0.54%，振幅4.13%。美国血液技术股票所在的医疗设备行业中，整体涨幅为0.78%。其相关个股中，Staar Surgical Company、Infusystems Holdings, Inc.、美国血液技术涨幅较大，Innovative Eyewear, Inc.、Sharps Technology Inc.、Bionano Genomics, Inc.较为活跃，换手率分别为2.01%、1.34%、1.02%，振幅较大的相关个股有Bionano Genomics, Inc.、Glucotrack, Inc.、Singular Genomics Systems, Inc.，振幅分别为11.10%、10.82%、8.19%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240927224921ab66863c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240927224921ab66863c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0106261612.USD","LU0205193047.USD","LU0205194284.USD","BK4198","LU0012050646.USD","LU1169589451.USD","LU1169590202.USD","IE00BLDYK493.USD","IE00B64QTZ34.USD","HAE"],"gpt_icon":0},{"id":"2461013243","title":"花旗：维持Haemonetics(HAE.US)评级，目标价由94.00美元调整至85.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461013243","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461013243?lang=zh_cn&edition=full","pubTime":"2024-08-23 08:32","pubTimestamp":1724373166,"startTime":"0","endTime":"0","summary":"花旗：维持Haemonetics(HAE.US)评级，由中性调整至中性评级,目标价由94.00美元调整至85.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082308472395b5d3e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082308472395b5d3e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HAE"],"gpt_icon":0},{"id":"2460373690","title":"美国血液技术2024财年第二财季实现净利润38.37百万美元，同比减少6.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460373690","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460373690?lang=zh_cn&edition=full","pubTime":"2024-08-18 00:00","pubTimestamp":1723910410,"startTime":"0","endTime":"0","summary":"8月18日，美国血液技术公布财报，公告显示公司2024财年第二财季净利润为38.37百万美元，同比减少6.51%；其中营业收入为3.36亿美元，同比增加8.04%，每股基本收益为0.75美元。从资产负债表来看，美国血液技术总负债16.36亿美元，其中短期债务5.11百万美元，资产负债比为1.56，流动比率为3.77。机构评级：截至2024年8月18日，当前有7家机构对美国血液技术目标价做出预测，其中目标均价为113.43美元，其中最低目标价为94.00美元，最高目标价为125.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800001495a162bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800001495a162bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HAE"],"gpt_icon":0},{"id":"2457131695","title":"美国血液技术盘中异动 股价大跌6.04%报80.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457131695","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457131695?lang=zh_cn&edition=full","pubTime":"2024-08-08 21:32","pubTimestamp":1723123941,"startTime":"0","endTime":"0","summary":"北京时间2024年08月08日21时32分，美国血液技术股票出现异动，股价大幅下挫6.04%。截至发稿，该股报80.54美元/股，成交量9614股，换手率0.02%，振幅4.64%。美国血液技术股票所在的医疗设备行业中，整体涨幅为0.56%。美国血液技术公司简介：美国血液技术公司旨在通过在血液和血浆成分采集、外科病房和医院输血服务空间提供医疗产品和解决方案，改善患者护理，降低医疗保健成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808213222a1d4278c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808213222a1d4278c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0106261612.USD","LU0205193047.USD","LU0205194284.USD","BK4198","LU0012050646.USD","LU1169589451.USD","LU1169590202.USD","IE00BLDYK493.USD","IE00B64QTZ34.USD","HAE"],"gpt_icon":0},{"id":"2457014995","title":"Haemonetics Corp   预计每股收益1.01美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2457014995","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457014995?lang=zh_cn&edition=full","pubTime":"2024-08-06 18:49","pubTimestamp":1722941363,"startTime":"0","endTime":"0","summary":"   * Haemonetics Corp    将于8月8日公布截至2024年6月30日的财报，预计季度收入将有所增长。* 根据LSEG的数据，6位分析师的平均预期显示，这家总部位于波士顿马萨诸塞州的公司的营收将从去年同期的3.1133亿美元增至3.3538亿美元，增幅为7.7%。* LSEG 分析师对 Haemonetics Corp 的平均预期为每股收益 1.01 美元。* 华尔街对 Haemonetics Corp 的 12 个月目标价中值为 115.00 美元，高于其上一交易日的收盘价 86.60 美元。8月6日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Haemonetics Corp   预计每股收益1.01美元 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HAE"],"gpt_icon":0},{"id":"2457901776","title":"美国血液技术盘中异动 早盘快速下挫5.73%报84.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457901776","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457901776?lang=zh_cn&edition=full","pubTime":"2024-08-05 22:00","pubTimestamp":1722866407,"startTime":"0","endTime":"0","summary":"北京时间2024年08月05日22时00分，美国血液技术股票出现异动，股价大幅下挫5.73%。截至发稿，该股报84.70美元/股，成交量4.0216万股，换手率0.08%，振幅1.56%。美国血液技术股票所在的医疗设备行业中，整体跌幅为2.23%。美国血液技术公司简介：美国血液技术公司旨在通过在血液和血浆成分采集、外科病房和医院输血服务空间提供医疗产品和解决方案，改善患者护理，降低医疗保健成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805220007af95fbf4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805220007af95fbf4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0205193047.USD","LU0205194284.USD","LU0012050646.USD","LU1169590202.USD","LU0106261612.USD","HAE","IE00BLDYK493.USD","LU1169589451.USD","IE00B64QTZ34.USD","BK4198"],"gpt_icon":0},{"id":"2455985754","title":"美国血液技术宣布Savvywire®预成形压力引导线获得CE认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2455985754","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455985754?lang=zh_cn&edition=full","pubTime":"2024-07-30 18:00","pubTimestamp":1722333633,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B64QTZ34.USD","BK4588","BK4585","LU1169590202.USD","LU0012050646.USD","LU0106261612.USD","LU0205194284.USD","LU0205193047.USD","LU1169589451.USD","CE","HAE","BK4109","BK4198","IE00BLDYK493.USD"],"gpt_icon":0},{"id":"2444468901","title":"美国血液技术推出新型Vascade Mvp Xl血管闭合装置的有限市场发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2444468901","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2444468901?lang=zh_cn&edition=full","pubTime":"2024-06-19 04:15","pubTimestamp":1718741724,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4198","IE00B64QTZ34.USD","LU1169590202.USD","HAE","LU1169589451.USD"],"gpt_icon":0},{"id":"2442381375","title":"美国血液技术 corp: Needham将其评级由持有调升至买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2442381375","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2442381375?lang=zh_cn&edition=full","pubTime":"2024-06-12 17:26","pubTimestamp":1718184381,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1169590202.USD","LU1169589451.USD","HAE","IE00B64QTZ34.USD","BK4198"],"gpt_icon":0},{"id":"2442485336","title":"用药贵、用药难，罕见病患者如何与药企共寻出路？ | 行业观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2442485336","media":"36氪","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2442485336?lang=zh_cn&edition=full","pubTime":"2024-06-11 13:52","pubTimestamp":1718085127,"startTime":"0","endTime":"0","summary":"文 | 常泽昱编辑 | 海若镜“如果连最终用药的患者到底需要什么都不知道，那么我们提供的可能都是我们想象的服务、是患者不需要的服务。”6月上旬由蔻德罕见病中心发起的行业案例研讨会上，谈及罕见病领域药物研发中“患者洞察”的重要性，百济神州创新业务拓展及全渠道营销总监杜珊珊总结道。罕见病患者的需求，核心在于“...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240611A04H4I00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240611A04H4I00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4198","LU1169590202.USD","BK1141","LU1169589451.USD","BK1576","BK1583","IE00B64QTZ34.USD","HAE","03347"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.haemonetics.com","stockEarnings":[{"period":"1week","weight":-0.0747},{"period":"1month","weight":0.1342},{"period":"3month","weight":0.1248},{"period":"6month","weight":-0.0387},{"period":"1year","weight":0.03},{"period":"ytd","weight":-0.0069}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":0.0118},{"period":"3month","weight":0.0616},{"period":"6month","weight":0.1153},{"period":"1year","weight":0.3028},{"period":"ytd","weight":0.2423}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Haemonetics Corporation成立于1971年，是一个全球性医疗设备公司,致力于为客户提供创新的血液管理解决方案——血浆来源收集者,采血机构和医院,在输血行业医疗设备系统方面有着强大的品牌优势,为客户提供解决方案的同时还提供信息技术平台和增值服务,其解决方案帮助患者改善临床结果，并提高血液中的供应链效率。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.01405},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.011877},{"month":3,"riseRate":0.69697,"avgChangeRate":0.022898},{"month":4,"riseRate":0.484848,"avgChangeRate":-0.025124},{"month":5,"riseRate":0.515152,"avgChangeRate":0.015931},{"month":6,"riseRate":0.588235,"avgChangeRate":0.019344},{"month":7,"riseRate":0.676471,"avgChangeRate":0.018801},{"month":8,"riseRate":0.735294,"avgChangeRate":0.029718},{"month":9,"riseRate":0.529412,"avgChangeRate":0.016681},{"month":10,"riseRate":0.5,"avgChangeRate":-0.006116},{"month":11,"riseRate":0.529412,"avgChangeRate":0.028854},{"month":12,"riseRate":0.606061,"avgChangeRate":0.028114}],"exchange":"NYSE","name":"美国血液技术","nameEN":"Haemonetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"美国血液技术(HAE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供美国血液技术(HAE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"美国血液技术,HAE,美国血液技术股票,美国血液技术股票老虎,美国血液技术股票老虎国际,美国血液技术行情,美国血液技术股票行情,美国血液技术股价,美国血液技术股市,美国血液技术股票价格,美国血液技术股票交易,美国血液技术股票购买,美国血液技术股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"美国血液技术(HAE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供美国血液技术(HAE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}